Livmarli
What Livmarli is used for
Livmarli is indicated for the treatment of: Cholestatic pruritus in patients with Alagille syndrome (ALGS) 2 months of age and older, Progressive familial intrahepatic cholestasis (PFIC) in patients 3 months of age and older. Livmarli tablets is indicated in adults and adolescents 12 years and older for the treatment of: Cholestatic pruritus in patients with Alagille syndrome (ALGS), Progressive familial intrahepatic cholestasis (PFIC).
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
- Approved under exceptional circumstances: full data cannot be collected, usually because the disease is very rare.
Key facts
- Brand
- Livmarli
- Active substance
- maralixibat chloride
- Disease area
- Alagille Syndrome
- Medicine group
- Other drugs for bile therapy
- ATC code
- A05AX04
- Marketing authorisation holder
- Mirum Pharmaceuticals International B.V.
- Authorised in the EU since
- 2022
Official information
In the USA
Same active substance: Livmarli
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Livmarli used for?
Livmarli is indicated for the treatment of: Cholestatic pruritus in patients with Alagille syndrome (ALGS) 2 months of age and older, Progressive familial intrahepatic cholestasis (PFIC) in patients 3 months of age and older. Livmarli tablets is indicated in adults and adolescents 12 years and older for the treatment of: Cholestatic pruritus in patients with Alagille syndrome (ALGS), Progressive familial intrahepatic cholestasis (PFIC).
What is the active substance in Livmarli?
Livmarli contains maralixibat chloride.
Who makes Livmarli?
The EU marketing authorisation holder is Mirum Pharmaceuticals International B.V..
Is Livmarli an orphan medicine?
Yes. Livmarli is designated an orphan medicine in the EU, for a rare disease (Alagille Syndrome).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU